WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 15, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that it will present at the Canaccord 35th
Annual Growth Conference at the Intercontinental Hotel in Boston on
Wednesday, August 12, 2015. Management is scheduled to present at 1:00
p.m. Eastern Time. A live audio webcast of the presentation may be
accessed by visiting the Investors page of AtriCure’s corporate website
A replay of the presentation will be available for 90 days following the
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of persistent and longstanding persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion
device is the most widely sold device worldwide that’s indicated for the
occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. Afib affects more than 33 million people worldwide.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150715006468/en/
Source: AtriCure, Inc.
Andy Wade, 513-755-4564
President and Chief Financial Officer